Pacific Biosciences of California, Inc.

NasdaqGS:PACB Stock Report

Market Cap: US$459.2m

Pacific Biosciences of California Future Growth

Future criteria checks 1/6

Pacific Biosciences of California is forecast to grow earnings and revenue by 36.8% and 18.7% per annum respectively. EPS is expected to grow by 39.2% per annum. Return on equity is forecast to be -41.3% in 3 years.

Key information

36.8%

Earnings growth rate

39.2%

EPS growth rate

Life Sciences earnings growth16.4%
Revenue growth rate18.7%
Future return on equity-41.3%
Analyst coverage

Good

Last updated28 Jan 2025

Recent future growth updates

Recent updates

Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Intrinsic Value Is Potentially 93% Above Its Share Price

Dec 10
Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Intrinsic Value Is Potentially 93% Above Its Share Price

Pacific Biosciences' Cost Cuts Won't Offset Rising Competition

Nov 12

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Rockets 56% But Many Are Still Ignoring The Company

Nov 07
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Rockets 56% But Many Are Still Ignoring The Company

Health Check: How Prudently Does Pacific Biosciences of California (NASDAQ:PACB) Use Debt?

Oct 16
Health Check: How Prudently Does Pacific Biosciences of California (NASDAQ:PACB) Use Debt?

Even With A 37% Surge, Cautious Investors Are Not Rewarding Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Performance Completely

Sep 20
Even With A 37% Surge, Cautious Investors Are Not Rewarding Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Performance Completely

Pacific Biosciences: A Speculative Play On Long-Read Genomics Sequencing

Aug 21

Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper

Jul 02
Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper

We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt

Jun 08
We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt

Pacific Biosciences: Navigating Rough Waters In Gene Sequencing Seas

Jun 03

These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat

Apr 25
These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat

It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks

Apr 16
It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks

Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership

Mar 19

Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth

Feb 08

With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For

Feb 01
With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For

What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S

Dec 18
What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S

Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?

Nov 13
Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?

The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%

Aug 28
The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?

Jul 31
Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?

Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Jul 06
Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt

May 25
Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt

Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Mar 29
Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?

Feb 26
Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?

Earnings and Revenue Growth Forecasts

NasdaqGS:PACB - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027312-135-36-485
12/31/2026246-177-93-6612
12/31/2025186-207-130-11614
12/31/2024155-374-252-19013
9/30/2024173-394-240-233N/A
6/30/2024189-400-261-253N/A
3/31/2024200-297-249-240N/A
12/31/2023201-307-268-259N/A
9/30/2023170-309-274-262N/A
6/30/2023146-319-275-260N/A
3/31/2023134-321-296-279N/A
12/31/2022128-314-280-263N/A
9/30/2022137-299-249-234N/A
6/30/2022140-206-224-212N/A
3/31/2022135-175-176-167N/A
12/31/2021131-181-117-111N/A
9/30/2021122-37-97-94N/A
6/30/2021106-77-73-71N/A
3/31/202192-59-80-79N/A
12/31/202079291820N/A
9/30/202080-461416N/A
6/30/202083-511516N/A
3/31/202090-532122N/A
12/31/201991-84-81-78N/A
9/30/201982-115-82-79N/A
6/30/201979-111-78-76N/A
3/31/201976-109-76-73N/A
12/31/201879-103-68-66N/A
9/30/201884-93-71-68N/A
6/30/201889-90N/A-71N/A
3/31/201888-93N/A-70N/A
12/31/201793-92N/A-68N/A
9/30/201794-90N/A-60N/A
6/30/201796-86N/A-58N/A
3/31/201797-79N/A-64N/A
12/31/201691-74N/A-68N/A
9/30/2016101-57N/A-56N/A
6/30/201690-37N/A-56N/A
3/31/201694-31N/A-44N/A
12/31/201593-32N/A-48N/A
9/30/201573-49N/A-63N/A
6/30/201580-60N/A-53N/A
3/31/201567-67N/A-59N/A
12/31/201461-66N/A-51N/A
9/30/201453-64N/A-51N/A
6/30/201440-76N/A-26N/A
3/31/201434-77N/A-29N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PACB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PACB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PACB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PACB's revenue (18.7% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: PACB's revenue (18.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: PACB is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 00:01
End of Day Share Price 2025/01/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pacific Biosciences of California, Inc. is covered by 24 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Luke SergottBarclays
Kyle MiksonCanaccord Genuity
Bryan BrokmeierCantor Fitzgerald & Co.